Patents by Inventor Ji Yun AHN

Ji Yun AHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
    Publication number: 20250082762
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Application
    Filed: November 15, 2024
    Publication date: March 13, 2025
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho KIM, Sung Yun CHO, Jae Du HA, Chi Hoon PARK, Jong Yeon HWANG, Hyun Jin KIM, Song Hee LEE, Ye Seul LIM, Han Wool KIM, Sun Mi YOO, Beom Seon SUH, Ji Youn PARK, Je Ho RYU, Jung Min AHN, Hee Jung MOON, Ho Hyun LEE
  • BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
    Publication number: 20250073341
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Application
    Filed: November 15, 2024
    Publication date: March 6, 2025
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho KIM, Sung Yun CHO, Jae Du HA, Chi Hoon PARK, Jong Yeon HWANG, Hyun Jin KIM, Song Hee LEE, Ye Seul LIM, Han Wool KIM, Sun Mi YOO, Beom Seon SUH, Ji Youn PARK, Je Ho RYU, Jung Min AHN, Hee Jung MOON, Ho Hyun LEE
  • Method for screening for autophagy activator or inhibitor
    Patent number: 10189900
    Abstract: The present invention provides a method for screening for an autophagy activator or inhibitor comprising the steps of: (a) making a test material to be analyzed come into contact with cells containing Beclin 1 protein; and (b) analyzing the degree of phosphorylation at the 30th serine amino acid residue of the Beclin 1 protein. The test material is determined to be an autophagy activator when the phosphorylation of the Beclin 1 protein is up-regulated, and the test material is determined to be an autophagy inhibitor when the phosphorylation of the Beclin 1 protein is down-regulated. The present invention first establishes, by ULK1, the mechanism of phosphorylation at the 30th serine amino acid residue of Beclin 1.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 29, 2019
    Assignees: KOREA FOOD RESEARCH INSTITUTE, REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Chang Hwa Jung, Tae Youl Ha, Ji Yun Ahn, Do Hyung Kim, Ji Man Park
  • METHOD FOR SCREENING FOR AUTOPHAGY ACTIVATOR OR INHIBITOR
    Publication number: 20170226202
    Abstract: The present invention provides a method for screening for an autophagy activator or inhibitor comprising the steps of: (a) making a test material to be analyzed come into contact with cells containing Beclin 1 protein; and (b) analyzing the degree of phosphorylation at the 30th serine amino acid residue of the Beclin 1 protein. The test material is determined to be an autophagy activator when the phosphorylation of the Beclin 1 protein is up-regulated, and the test material is determined to be an autophagy inhibitor when the phosphorylation of the Beclin 1 protein is down-regulated. The present invention first establishes, by ULK1, the mechanism of phosphorylation at the 30th serine amino acid residue of Beclin 1.
    Type: Application
    Filed: July 2, 2014
    Publication date: August 10, 2017
    Inventors: Chang Hwa JUNG, Tae Youl HA, Ji Yun AHN, Do Hyung KIM, Ji Man PARK